$591.17
-2.14-0.36%
At close: Nov 13, 4:00 PM EST
$591.17
N/A
After Hours: 5:44 PM EST
United Therapeutics Corp
UTHRNASDAQ
United Therapeutics rose 27.2% from $466.40 to $593.31, ahead of the S&P 500's +12.3%. Its worst day was Nov 5 (−7.0%), and its low came Jan 16 at $464.93.
Nov 14, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
United Therapeutics closed at its lowest level of the year, 0.3% below where the year started.
−1.5% · S&P 500 −0.1%
EPS of $7.70 beat the $6.77 estimate on $790.2M revenue (est. $808.9M).
Story events cover the past 12 months · Times ET
+13.0%, the year's best day · S&P 500 +0.8%
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of Directors has authorized a new stock repurchase program of up to $2 billion over the next year.
+10.7% · S&P 500 +0.9%
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-1 study evaluating the use of nebulized Tyvaso for the treatment of idiopathic pulmonary fibrosis (IPF) met its
+12.5% · S&P 500 −0.3%
EPS of $5.82 missed the $6.83 estimate on $781.5M revenue (est. $798.0M).
+4.3% · S&P 500 +1.4%
EPS of $7.27 beat the $6.86 estimate on $783.3M revenue (est. $807.0M).
+0.1% · S&P 500 −0.2%
United Therapeutics shares rose 12.5%, while the S&P 500 fell 0.2%.
+12.5%, on 3M shares, the year's heaviest volume · S&P 500 −0.2%
EPS of $5.71 missed the $6.00 estimate on $832.5M revenue (est. $781.6M).
+1.2% · S&P 500 +1.7%
Where it ended: a close of $593.31 on Nov 12, 2026. Up next: Q4 2026 earnings on Feb 24, 2027 (EPS est. $5.38, revenue est. $853.5M).
Nothing in the past 12 months.
All UTHR dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for UTHR and SPY from Benzinga historical bars. Not investment advice.
